Trastuzumab - Hermab 440mg injection online | Myapplepharma
Trastuzumab - Hermab
440mg injection online | Myapplepharma
Hermab 440mg is a group of medicines which belongs to
anti neoplastic medication. Hermab 440mg is a
chemotherapy drug. It is recommended that Hermab 440mg be
administered under the guidance of a qualified physician experienced in the use
of cancer chemotherapeutic agents.
USES
- The Hermab 440mg injection is
used alone or combination with other medicine for the treatment in patients
who suffering from metastatic breast cancer.
- The drug also indicated with
combination of other medicine for the treatment of certain types of
stomach or esophagus cancer in some persons.
WORK AS
- Different type of breast cancer
cells has a higher than normal level of a protein called HER2 (human
epidermal growth factor receptor 2) on their surface. These HER2 receptors
get signals which stimulate the tumor cells to develop and reproduce. But
breast cancer cells with too many HER2 receptors can Choice too many
growth signals and so start developing and proliferating too much and too
fast.
- Hermab acts
by adhere itself to the HER2 receptors on the surface of breast cancer
cells and stopping them from collecting growth signals. By stopping the
signals, Hermab can slow or inhibit the growth
of the breast cancer and the drug is an immune targeted therapy. In
addition to inhibiting HER2 receptors, Trastuzumab can also help to fight
against breast cancer by attentive the immune system to damage the cancer
cells onto which it is attached.
- The injection
Hermab should not mix with other drugs and do not administer as an
intravenous push or bolus.
- Trastuzumab
should not be substitute for or with ado-Trastuzumab emtansine
Adjuvant
treatment, breast cancer:
- The drug given
according to one of the following doses and schedules for a 52 weeks total
of trastuzumab treatment:
- During
combination with paclitaxel, docetaxel, or docetaxel /Carboplatin:
- Starting dose
of 4 mg/kg as an IV (intravenous infusion) over 90 minutes followed at 2
mg/kg as an IV(intravenous infusion) over 30 minutes weekly during
treatment of chemotherapy given with paclitaxel or docetaxel for first 12
weeks or 18 weeks (docetaxel/carboplatin) The Hermab dose for One week
following the last weekly administers Trastuzumab at 6 mg/kg as an IV
(intravenous infusion) over 30 to 90 minutes every three weeks.
The injection given as a single agent within
three weeks following completion of multi-modality, anthracycline-based
chemotherapy regimens:
For an intravenous infusion over 90 minutes: Initial dose at 8 mg/kg
Successive doses at 6 mg/kg over 30 to 90 minutes every three weeks as an intravenous infusion.
Adjuvant treatment stretching beyond one year is not recommended.
Metastatic Treatment, Breast Cancer:
Hermab administrated alone or in combination with paclitaxel, at a starting dose of 4 mg/kg as a 90-minute intravenous infusion continued by successive once weekly doses of 2 mg/kg as 30-minute intravenous infusions until disease development.
Metastatic Gastric Cancer:
Hermab administrated at a starting dose of 8 mg/kg as a 90-minute IV intravenous infusion continued by successive doses of 6 mg/kg as an intravenous infusion over 30 to 90 minutes every three weeks until disease development.
For an intravenous infusion over 90 minutes: Initial dose at 8 mg/kg
Successive doses at 6 mg/kg over 30 to 90 minutes every three weeks as an intravenous infusion.
Adjuvant treatment stretching beyond one year is not recommended.
Metastatic Treatment, Breast Cancer:
Hermab administrated alone or in combination with paclitaxel, at a starting dose of 4 mg/kg as a 90-minute intravenous infusion continued by successive once weekly doses of 2 mg/kg as 30-minute intravenous infusions until disease development.
Metastatic Gastric Cancer:
Hermab administrated at a starting dose of 8 mg/kg as a 90-minute IV intravenous infusion continued by successive doses of 6 mg/kg as an intravenous infusion over 30 to 90 minutes every three weeks until disease development.
Embryo fetal damage
Hermab 440mg is contraindicated to pregnancy period.
Avoid becoming pregnancy during this therapy. Use efficient contraceptives
during treatment
Cardiomyopathy
Patient getting Hermab 440mg injection have
increased risk of exposing to cardiac disorders. Provide alternative therapy
management In serious condition, treatment should be discontinuing
Pulmonary toxicity
Some serious fatal cases
of pulmonary toxicity occur during Hermab 440mg treatment.
Infusion reactions
During Hermab 440mg treatment some
life-threatening infusion reactions are produced. In serious infusion
reactions, Stop the Hermab 440mg treatment
permanently. Patient should be treated with premedication before starting the
infusion to overcome the such problem, During Hermab 440mg treatment. Use with
Caution.
Therapy induced
neutropenia
Higher incidence of
neutropenia occurs during Hermab 440mg treatment.
DRUG INTERACTION
In some phenomenal
condition, patient should get anthracycline, in that situation patient’s
cardiac function should be checked carefully with regular intervals.
Do not take anthracycline treatment for 7 months after stopping the Hermab 440mg treatment.
Hermab 440mg interaction with anthracycline after ending of Hermab 440mg treatment may have a chance of getting cardiac problem. This side effects occur because of Trastuzumab great disaster period is depends on population PK analysis.
Do not take anthracycline treatment for 7 months after stopping the Hermab 440mg treatment.
Hermab 440mg interaction with anthracycline after ending of Hermab 440mg treatment may have a chance of getting cardiac problem. This side effects occur because of Trastuzumab great disaster period is depends on population PK analysis.
CONTRAINDICATION
Probably no
contraindicated occurs. The patients are contraindicated to the component
present in the Hermab 440mg, Hence
Hypersensitivity reactions are occurring.
STORAGE
Store the drug at 2℃ to 8℃ (refrigerator temperature) Protected the vial
away from heat & light Stored at 2℃ to 8℃ for 28 days after reconstitution Stored Hermab 440mg diluted bag at 2℃ to 8℃ for 24 hours.
MISSED DOSE
The drug Missing doses
can decrease their usefulness and raises the probability of developing drug
resistance, that makes this drug lose their potency. For best results, it is
important to accept each scheduled dose of Trastuzumab medication as
instructed. If you miss a dose, leave the missed dose and continue with your
regular dosing schedule. Do not have two doses to make up for a missed one. If
you are not sure about what to do after missing a dose, the take advice with
doctor or pharmacist.
SIDE EFFECTS
Common side effects:
- Redness at injection site (IV)
- Muscle/joint/back pain
- Insomnia
- Tiredness
- Mild skin rash
- Stuffy nose
- Sinus pain
Serious side effects:
- Increased coughing
- Sudden unexplained weight gain
- Unusual tiredness
- Easy bruising or bleeding
- Fast or pounding heartbeat
- Increased coughing
CONTACT DETAILS
Phone : 9987711567
Email
: applepharmaceutical@gmail.com
Email : info@myapplepharma.com
Comments
Post a Comment